Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update  by Hertig, Alexandre & Zuckermann, Andreas
Transplant Immunology 32 (2015) 179–187
Contents lists available at ScienceDirect
Transplant Immunology
j ourna l homepage: www.e lsev ie r .com/ locate / t r imReviewRabbit antithymocyte globulin induction and risk of post-transplant
lymphoproliferative disease in adult and pediatric solid organ
transplantation: An updateAlexandre Hertig a,⁎, Andreas Zuckermann b
a AP-HP, Hôpital Tenon, Urgences Néphrologiques et Transplantation Rénale, Sorbonne Universités, UPMC, Paris CEDEX 6, France
b Department of Cardiac Surgery, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, AustriaAbbreviations: AHR, adjusted hazard ratio; ALG, antil
antithymocyte globulin; ATGAM, equine thymocyte glob
Transplant Study; DSA, donor-speciﬁc antibodies; EBV, Ep
Heart and Lung Transplantation;MMF,mycophenolatemo
Transplantation Network; PTLD, post-transplant lymphop
UNOS, UnitedNetwork of Organ Sharing; USRDS,United St
⁎ Corresponding author. Tel.: + 33 1 56 01 70 00.
E-mail address: alexandre.hertig@tnn.aphp.fr (A. Hert
http://dx.doi.org/10.1016/j.trim.2015.04.003
0966-3274/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 24 February 2015
Received in revised form 21 April 2015
Accepted 24 April 2015
Available online 30 April 2015
Keywords:
PTLD
Rabbit antithymocyte globulin
rATG
Thymoglobulin
Lymphoma
Kidney transplantationThe most modiﬁable risk factor for post-transplant lymphoproliferative disease (PTLD) is the type and dose of
induction andmaintenance immunosuppressive therapy. It is challenging to identify the contribution of a single
agent such as rabbit antithymocyte globulin (rATG) in the setting of multidrug therapy. Registry analyses can be
helpful but are limited by methodological restrictions and inclusion of historical patient cohorts. These are
typically from eras when rATG dosing wasmarkedly higher than current dosing (e.g. total dose 14mg/kg versus
6 mg/kg now), accompanied by higher exposure to maintenance therapies, and often an absence of antiviral
prophylaxis. The largest registry analysis to assess rATG speciﬁcally found no risk of PTLD after kidney transplan-
tation, but conﬂicting results have been reported, highlighting the difﬁculty of interpreting this type of analysis.
The relative rarity of PTLD means that individually controlled trials are underpowered to assess its occurrence,
but the available data do not suggest an effect of rATG. A pooled analysis of data from studies of rATG induction
in kidney and heart transplantation found the incidence of PTLD to be comparable to published reports in the
overall transplant population. Data on the effect of rATG dose are inconclusive, but in patients receiving antiviral
prophylaxis it does not appear to be inﬂuential. Nevertheless, it would seem reasonable to employ the lowest
dose of rATG compatible with effective induction, particularly in EBV-seronegative recipients and other high-
risk groups such as heart–lung transplant recipients. Overall, the risk of PTLD following rATG induction therapy
withmodern dosing regimens and under currentmanagement conditions appears unlikely tomake an important
contribution to the risk:beneﬁt balance.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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1.1. Epidemiology and risk factors
Post-transplant lymphoproliferative disorder (PTLD) remains a rare
but important complication of solid organ transplantation. While it
can remain a benign lymphoid hyperplasia in some cases, in others
the B-cells mutate and can progress to high-grade, life-threatening lym-
phomas such as non-Hodgkin lymphoma (NHL). Although improved
management has helped to improve outcomes [1], mortality rates
remain substantially higher after the diagnosis of PTLD [2–5].
Various risk factors for PTLD have been proposed, of which recipient
seronegativity for Epstein–Barr virus (EBV) with engraftment from an
EBV-positive donor is the most important and well-documented,
conferring more than a 20-fold increase in risk [6]. Up to 50% of PTLD
cases are EBV-related [7]. The risk of developing PTLD is organ-
speciﬁc, with higher rates of both PTLD [8] and NHL [9] following
heart, lung and intestinal transplantation where higher doses of
immunosuppression are required. An analysis of over 100,000 patients
receiving a primary kidney transplant during 2000–2009 found the
ﬁve-year incidence of PTLD to be 0.84% [10], compared to N1.0% in
heart transplant patients [11]. Recipients of a lung or heart–lung trans-
plant are at the highest risk due to the lymphoid-rich nature of lung
tissue and importation of high levels of EBV from the donor. Age is
also important: children are more likely to develop PTLD than adults
[12–15] due to higher rates of seronegativity for EBV. Other possible
risk factors include recent infection with cytomegalovirus (CMV) or
CMV-seronegativity at time of transplant [16–18]. Clinical studies have
provided robust evidence that CMV prophylaxis with virostatic agents
and/or CMV immunoglobulin therapy can substantially reduce the risk
of EBV-associated PTLD [19–21].1.2. The role of immunosuppressive therapies
One of themost modiﬁable risk factors for PTLD is the type and dose
of immunosuppressive therapy [22]. Although transplant recipients
usually maintain some level of EBV-speciﬁc cytotoxic CD8+ T-cells,
this can vary and regimens which more intensively suppress T-cell
count or function would be expected to increase the risk of PTLD.
Widespread adoption of calcineurin inhibitor (CNI) therapy was
associated with a signiﬁcant increase in risk of NHL [23,24]. CNI agents
are almost universally prescribed, at least in the immediate post-
transplant period, with some evidence suggesting a higher risk for
PTLD under tacrolimus versus cyclosporine [10,25]. Mycophenolate
mofetil (MMF) does not appear to affect risk for PTLD [24,26]. Mamma-
lian target of rapamycin (mTOR) inhibitors may be risk-neutral or
potentially reduce risk by inhibiting growth signals in PTLD-associated
EBV+ B-cell lymphomas [27]. There is evidence that mTOR inhibition
blocks the replication of EBV-positive B-cells, T-cells and natural killer
(NK) cells [28,29]. Treatment of rejection with high-dose steroids can
adversely affect risk for PTLD [30]. For the costimulation blocker
belatacept, an inhibitor of T-cell proliferation, PTLD risk appears similar
to that seen under CNI therapy [31] but, of note, belatacept is contrain-
dicated in EBV-seronegative recipients. Against this complex back-
ground, the contribution of a single element in the multidrug
induction-maintenance regimen cannot be accurately identiﬁed with
conﬁdence.Particular interest has focused on the effect of lymphocyte-depleting
induction therapies. The International Society for Heart and Lung
Transplantation (ISHLT) guidelines state that polyclonal induction agents
maybe beneﬁcial to delay CNI introduction in patients at high risk of renal
dysfunction and that antithymocyte globulin (ATG) induction may be
beneﬁcial in thoracic organ recipients at high risk for acute rejection
[32], based on analyses comparing rabbit ATG (rATG, Thymoglobulin®)
versus basiliximab induction [33,34]. The efﬁcacy of rATG versus IL-2RA
induction in facilitating delayed CNI therapy after kidney transplantation
has also been demonstrated [35], although it is uncertain whether this
strategy affects the risk of delayed graft function [36].
The ISHLT guidelines also comment that routine use of induction
therapy with polyclonal preparations is indicated when complete
steroid avoidance is planned. Lymphocyte-depleting agents such as
muromonab -CD3 [OKT3], antithymocyte antibodies and antilymphocyte
preparations can induce a profound decrease in T-cell counts. During
the 1980s and early 1990s, when muromonab OKT3 and non-rATG
preparations were becoming more widely used [37,38], a marked
increase in the incidence of PTLD was observed [13,39]. From the late
1990s onwards, however, rATG became the most commonly used
polyclonal agent in the US, with equine antithymocyte globulin
(ATGAM) and OKT3 becoming virtually obsolete [37,38]. Today, rATG
is the most frequently administered lymphocyte-depleting agent
worldwide [40]. In addition to its effect on T-cells, rATG also exerts a
wide spectrum of immunomodulatory effects, targeting B-cells, plasma
cells, monocytes and dendritic cells [41].
Thequestion ofwhether rATG is associatedwith an increased risk for
PTLD after solid organ transplantation is considered here in the context
of contemporary management practices.2. Evidence from registry analyses
2.1. Interpreting registry data
The relative rarity of PTLD means that randomized trials cannot
include adequate patient numbers to provide meaningful data on
relative risk according to immunosuppressive regimen. Moreover, the
time to onset of PTLD – a median of up to seven years post-transplant
in adult kidney transplant patients [42] and three years in children
[43] – means that the duration of controlled trials is often inadequate.
Single-center retrospective studies can offer larger numbers, with
longer follow-up, but the most substantial data are derived from
analyses of transplant registry databases. Registry data, however, must
be considered carefully due to a number of potential weaknesses
(Table 1). Data from patients transplanted from the 1980s onwards
are frequently included to provide sufﬁcient numbers and follow-up,
but must be regarded cautiously since rATG dosing was markedly
higher than now [44]. Since higher rATG dosing is associated with a
higher risk for PTLD [11], this is an important consideration. Transplant
registries do not record rATG dosing, so it cannot be established wheth-
er analyzed cohorts received doses compatible with contemporary
regimens but this seems unlikely. Opelz et al. have shown a trend to
lower rates of NHL in kidney and heart transplant patients receiving
ATG induction from the period 1985–1989 to 1995–2001, based on
data from the Collaborative Transplant (CTS) study database [9].
While dosing information is not available, this may have been due to
lower doses over time.
Table 1
Considerations for registry analyses of induction therapy and PTLD.
Long analyses periods Requirement for large numbers and extended
follow-up frequently necessitates inclusion of
many years' data, during which management
can evolve substantially.
Historical data Many published registry analyses of PTLD risk
only include transplants up to the early 2000s.
Selective use of rATG rATG induction is preferentially used in patients
at high immunological risk who tend to receive
more intensive immunosuppression. This bias
may not be fully accounted for even in
multivariate analysis.
Combined analyses Analyses often report PTLD risk for ‘polyclonal
antibodies’ or ‘ATG’ instead of speciﬁcally rATG.
Mixed analysis of induction
and anti-rejection therapy
Dosing for treatment of rejection tends to be
higher than for induction regimens and
represents an additional immunosuppressive
load following induction.
Lack of dosing data Registries typically do not record dosing but
rATG dose has declined over time.
EBV status often lacking EBV serostatus cannot be included as a
covariate.
Multidrug regimens Maintenance immunosuppression choice
is not always included as a covariate.
Varying endpoints PTLD, NHL or lymphoma
EBV, Epstein–Barr virus; NHL, non-Hodgkin lymphoma; PTLD, post-transplant lympho-
proliferative disorder; rATG, rabbit antithymocyte globulin.
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by multivariate analysis, but since data collection by registries is neces-
sarily limited all relevant covariates (e.g. recipient EBV serostatus)
cannot always be included. Moreover, outcomes for collective groups
of induction agents (e.g. ‘polyclonal induction agents’ or ‘ATG’) cannot
be regarded as applying to rATG, since there are clear differences in
the risk of PTLD associatedwith different preparations [45,46]. It should
also be noted that some studies include the use of agents either as
induction therapy or as anti-rejection therapy, although those patients
given anti-rejection therapy incur a substantial additional immunosup-
pressive load, often after receiving induction therapy. Additionally, the
frequency of PTLDhas declined over time, adding a further complication
to analyses of transplants over a long period. Caillard et al. analyzed data
from over 20,000 kidney transplants performed in France during 1998
to 2007 and found a three-fold decrease in incidence from the early
years to 2006–2007 [4]. As a further complication, a comparison of
PTLD data obtained via the Organ Procurement and Transplantation
Network (OPTN) or via Medicare claims in the US found that the one-
year incidence of PTLD after kidney transplantation was twice as high
based on Medicare claims, indicating that data collection on PTLD by
transplant registries is incomplete [5].
Thus, while helpful, the results of registry analyses must be
examined carefully.
2.2. Registry ﬁndings: PTLD
Table 2 summarizes the registry analyses that have assessed the risk
of PLTD or NHL according to use of rATG speciﬁcally or various combina-
tions of lymphocyte-depleting agents, either for induction only or
induction and anti-rejection treatment combined. Each of these analy-
ses has the important limitation that data were included from the
1990s or even the 1980s, and often only up to the early or mid-2000s.
It is reasonable to assume that rATG dosing would be higher than is
typical now for the bulk of patients in these studies.
Of the three analyses that considered rates of PLTD according to
whether rATG induction, speciﬁcally, was given or not [15,17,47], two
found a signiﬁcantly higher risk in rATG-treatedpatients versus patients
without rATG [17,47] while one found no signiﬁcant association [15].
Surprisingly, in their analysis published in 2004, Bustami et al. found
the relative risk (RR) of PLTD to be signiﬁcantly increased not only byrATG but also by interleukin-2 receptor alpha (IL-2RA) induction
using basiliximab or daclizumab [47]. Indeed, the risk associated with
IL-2RA induction was found to be higher than with OKT3 induction
(RR 1.92 with daclizumab, 1.83 with basiliximab and 1.71 with OKT3).
No signiﬁcant difference in risk between the types of induction therapy
was detected. These unexpected results are not consistent with the
literature, which indicates no pro-malignancy effect of IL-2RA induction
[51,54] or, indeed, a protective effect [4,5]. In a larger series (n =
98,907), Dharnidharka and colleagues found the rate of PTLD at a
median follow-up of 368 days to be 0.50% (60/12,051) in patients
given rATG induction [15]. In patients given no induction, the rate of
PTLD was 0.56% (272/48,133), representing an adjusted relative risk
(aRR) of 1.17 (95% CI 0.87, 1.58) (p = 0.29). The same group also
assessed PTLD in the subpopulation of children (n = 5072). The
incidence of PLTD in the 685 children given rATG was 1.90%, not signif-
icantly different to the rate of 1.44% in children given no induction
(aRR 1.51, 95% CI 0.78, 2.93) [15]. In contrast, Kirk and colleagues
found rATG induction to be associated with an increase risk of PTLD
versus no induction in a series of kidney transplants performed during
2000 to 2004 [17] (Table 2). The incidence of PTLD in rATG-treated
patients was 0.67% by day 730 (at which point data were censored),
representing an RR of 1.630 (p = 0.0025) versus no induction.
Other registry studies of PTLD risk [5,16,48–50] have groupedmulti-
ple lymphocyte-depleting induction agents together for the purpose of
analysis, in some cases including OKT3. These have shown inconsistent
results (Table 2). One of these analyses considered the risk of PTLD in
children undergoing heart transplantation [49]. In a cohort of 1258
children transplanted during 1993 and 2007, the risk of PTLD was
assessed according to induction (Table 2). Multivariate analysis showed
that the group given rATG (n = 246), other ATG preparations (n =
329), antithymocyte serum (n = 231) or IL-2RA (n = 244) induction
were at a signiﬁcantly reduced risk for lymphoma versus those given
no induction (hazard ratio [HR] 0.45; 95% CI 0.25, 0.82; p = 0.009)
[49]. Overall, however, since neither the speciﬁc type of induction nor
the dose or duration of therapy was recorded, the ﬁndings of these
studies which included groups of different induction agents are of
limited value when considering rATG speciﬁcally.
Overall, registry evidence concerning the relationship between rATG
and risk of PTLD is mixed, and in view of the imperfect methodology no
deﬁnite conclusions can be drawn.
2.3. Registry ﬁndings: NHL
Of the analyses which examined the occurrence of NHL, rather than
the wider endpoint of PLTD, only one included rATG therapy exclusive-
ly, and limited this to induction use [46]. In this study, the risk of NHL
was assessed based on data from the international CTS derived from
ﬁrst deceased-donor kidney transplants undertaken during 1984 to
2004 [46]. rATG induction was found to increase the risk of NHL signif-
icantly compared to no induction, with a standardized incidence ratio
for NHL of 21.6 for rATG-treated patients versus 9.4 for patients without
induction (p= 0.002). However, again it is difﬁcult to apply these ﬁnd-
ings to current practice. Approximately half the patients given rATG
were transplanted during 1985–1994, and half during 1995–2004,
since when rATG dosing has declined substantially [44,55,56]. Over
this 20-year period there have also been very substantial reductions in
exposure to maintenance immunosuppressive therapies, notably CNIs
and steroids, which was not taken into account. The effect of mainte-
nance therapy is likely to dominate over the latter part of the three-
year follow-up, when PTLD incidence continued to rise. The CTS also
includes a large and highly diverse group of centers from around the
world, such that management practices were likely to vary widely.
Studies in which rATG was grouped with other lymphocyte-
depleting agents (as induction and, in some cases, also anti-rejection
therapy) have shown either a higher risk of lymphoma [24,51,52] or
no effect [53], but as for PTLD it is difﬁcult to draw relevant conclusions.
Table 2
Registry analyses of PTLD or NHL according to use of rATG or lymphocyte-depleting therapy in solid organ transplant populations.
Study n Registry Time of transplant Follow-up Treatment group Comparator group Outcomes (treatment group
vs comparator group)
PTLD
Cherikh et al. [16] 38,519 (kidney) OPTN 1997–2000 ≤727 days ATG (type not speciﬁed), ALG or ATGAM
(induction or anti-rejection)
No ATG, ALG or ATGAM No increase in PTLD
RR 1.29 (95% CI 0.82, 2.03)
p = 0.27
Bustami et al. [47] 41,686 (kidney) SRTR 1995–2002 ≤6 years rATG (induction only) No induction Higher risk of PTLD
RR 3.00 (95% CI 1.53, 5.89)
p = 0.001
Dharnidharka et al. [15] 84,907 (kidney) UNOS 1987–2003 Median 368 days
(rATG group)
rATG (induction only) No induction No increase in PTLD
ARR 1.17 (95% CI 0.87, 1.58)
p = 0.29
Faull et al. [48] 13,516 ANZDATA 1970–2003 Not speciﬁed T-cell depleting (induction or anti-rejection) No T-cell depleting therapy No increase in PTLD
HR 1.2
95% CI 0.90, 1.7
p = 0.18
Kirk et al. [17] 59,560 (kidney) OPTN 2000–2004 ≤730 days rATG (induction only) No induction Higher risk of PTLD
ARR 1.630 (95% CI 1.188, 2.235)
p = 0.0025
Kasiske et al. [5] 89,485 (kidney) OPTN 2000–2006 ≤3 years T-cell depleting (induction only) No inductiona Higher risk of PTLD
HR 1.55 (1.19, 2.01)
p = 0.001
Gajarski et al. [49] 2374 (heart) Pediatric Heart Transplant
Study
1993–2007 5 years rATG, ATG, ATS or IL-2A (induction only) No induction Lower risk of PTLD
HR 0.45
95% CI 0.25, 0.81
p = 0.009
Caillard et al. [50] 21,352 (kidney) French PTLD registry 1998–2007 ≤10 years ATG or OKT3 (induction or rejection) No ATG or OKT3 Borderline higher risk of PTLD
AHR 1.42 (95% 1.00, 2.02)
p = 0.05
Lymphoma
Caillard et al. [51] 25,127 (kidney) USRDS 1996–2000 3 years ATG (induction or anti-rejection) No ATG Higher risk of NHL
AHR 1.55 (95% CI 1.2, 1.99)
p = 0.001
Caillard et al. [52] 66,159 (kidney) USRDS 1991–2000 ≤10 years ATG (induction or anti-rejection) No ATG Higher risk for NHL
AHR 1.37 (95% 1.17, 1.6)
p b 0.05
Opelz et al. [46] 112,122 (kidney) CTS 1985–2004 3 years rATG (induction only) No induction Higher risk of NHL
SIR 21.6 vs 9.4
p = 0.002
van Leeuwen et al. [24] 8,164 (kidney) ANZDATA 1982–2003 Not speciﬁed ATG, ALG or OKT3 (induction or rejection) No ATG, ALG or OKT3 Higher risk of NHL
IRR 2.39 (95% CI 1.08, 5.30)
p = 0.031
Hall et al. [53] 111,857 (kidney) SRTR 1987–2009 Median 3.5 years ATG, ALG (induction only) No ATG or ALG No increase in NHL
ARR 0.96 (95% CI 0.77, 1.20)
p = 0.7
AHR, adjusted hazard ratio; ALG, antilymphocyte globulin; ANZDATA, Australia and New Zealand Dialysis and Transplant Registry; ARR, adjusted relative risk; ATG, antithymocyte globulin; ATGAM, equine thymocyte globulin; ATS, antithymocyte
serum; CI, conﬁdence interval; CTS, Collaborative Transplant Study; HR, hazard ratio; IL-2RA, IL-2 receptor antagonist; IRR, incidence rate ratio; NHL, non-Hodgkin lymphoma; OPTN, Organ Procurement and Transplant Network; PTLD, post-trans-
plant lymphoproliferative disorder; rATG, rabbit antithymocyte globulin; RR, relative risk; SIR, sirolimus; SRTR, Scientiﬁc Registry for Transplant Recipients; UNOS, United Network of Organ Sharing; USRDS, United States Renal Data System.
a Includes 10 patients receiving induction other than T-cell depleting or IL-2RA induction.
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plants is limited. In one analysis from the CTS, Opelz et al. reported
that ATG induction (including all ATG preparations) ‘did not confer an
added risk for lymphoma’ in heart transplant recipients, but further
information was not provided [9]. A prospective cohort study of all UK
transplant centers has reported rates of death due to malignancy
following heart transplantation according to whether patients received
ATG of any type, or no ATG [57]. The population of 2086 patients was
transplanted during 1995 to 2008, and thus represents a relatively
recent cohort. Univariate analysis showed no effect of ATG on death
from either lymphoid malignancy (1.0% versus 1.4% in non-ATG treated
patients, p= 0.38) or non-lymphoidmalignancy (3.9% versus 2.8%, p=
0.40); no multivariate analysis was performed.
2.4. Registry data on anti-rejection treatment
An association between rATG treatment for rejection episodes and
PTLD has been less well examined. Lim et al. recently evaluated data
from 7153 patients transplanted during 1997 to 2009 who received
anti-rejection therapy and who were registered with the Australian
and New Zealand Dialysis and Transplant Registry (ANZDATA)
[58]. Treatment for rejection with a T-cell depleting antibody
(ATG, antilymphocyte globulin [ALG] or OTK3) was associated with a
higher rate of malignancy of any type versus patients with no rejection
(adjustedHR [AHR] 1.42; p=0.039). No statistical comparisonwasper-
formed versus patients with rejection treated without T-cell depleting
antibody and speciﬁc types of induction agent were not compared [58].
3. Prospective studies
No prospective study of rATG in solid organ transplantation, either
as induction or anti-rejection therapy, is adequately large to provide
interpretable data on the risk of PTLD. As shown in Table 3, reports of
PTLD are extremely rare in randomized trials. In the largest trial, by
Brennan et al., 278 kidney transplant patients were randomized to a cu-
mulative rATG dose of 7.5 mg/kg or basiliximab (40 mg in total), bothTable 3
Prospective, randomized trials reporting PTLD following rATG induction.
Study N Follow-up (months) PTLD (% patients)
Kidney transplants
Brennan et al. [59] 72 60 rATG 0a
ATGAM 0a
Mourad et al. [60] 105 12 rATG 0
Basiliximab 0
Brennan et al. [61] 278 12 rATG 2.1b,c
Basiliximab 0b, c
Abou-Ayache et al. [62] 109 12 rATG 0
Daclizumab 0
Noël et al. [63] 227 12 rATG 0d
Daclizumab 0d
Liver transplants
Bogetti et al. [64] 22 3 rATG 0
No induction 0
Boillot et al. [65] 93 60 rATG 0
No induction 0
Heart transplants
Mattei et al. [66] 80 6 rATG 0
Basiliximab 0
Yamani et al. [67] 32 12 rATG 6 mg/kg 0
rATG 1.5 mg/kg 0
ATGAM, equine thymocyte globulin; PTLD, post-transplant lymphoproliferative disorder;
rATG, rabbit antithymocyte globulin.
a Follow-up to year 5: no PTLD in the rATG group, 8.3% PTLD in the ATGAM group [68].
b p = 0.13 versus basiliximab.
c Follow-up to year 5: 1.2% PTLD in the rATG group, 0% PTLD in the basiliximab
group (p = n.s.) [63].
d Follow-up to year 5: no deaths due to PTLD in the rATG group, 1 death due to PTLD
in the rATG group [69].with cyclosporine, MMF and steroids [61]. At one year, there were
three cases of PTLD in the rATG group and none in the basiliximab
group, a difference that was not signiﬁcant. No other cases of PTLD
have been reported in randomized trials of rATG after solid organ trans-
plantation. Three randomized trials [59,61,63] followed patients to ﬁve
years after kidney transplantation. In one of these, involving 72 patients
[59], there were no cases of PTLD in the rATG cohort compared to an in-
cidence of 8.3% in the ATGAM cohort at the end of ﬁve years' follow-up
[68]. The second trial, which enrolled a larger cohort of 227 kidney
transplant patients [63], reported one death from PTLD in the
daclizumab group with none in the rATG arm, by ﬁve years' follow-up
[69]. In the third study [61], the ﬁve-year incidence of PTLDwas similar
in the cohort treated with rATG (1/91, 1.2%) or basiliximab (0%; p =
n.s.) [70]. No robust conclusions can be drawn other than that prospec-
tive trials do not provide data to indicate a higher rate of PTLD following
rATG induction in solid organ transplant patients.
4. Retrospective studies
Few comparative retrospective studies have described the incidence
of PTLD or NHL according to type of induction, even when
antithymocyte preparations other than rATG are considered. Several
of the available reports do not differentiate between types of
lymphocyte-depleting induction therapy. Analyses which included pa-
tients treated with OTK3 [8,71,72], in particular, are of limited value
when assessing an effect of rATG in view of the profound increase in
lymphoma risk associated with OKT3 [16,46,53]. Table 4 summarizes
the most relevant retrospective studies. One large analysis of 763 pa-
tients undergoing kidney transplantation during 1995 to 2001 found
no cases of PTLD in any induction-treated patient, but only 213 individ-
uals received induction and only 71 were given rATG [73]. Two other
large retrospective analyses did not speciﬁcally consider rATG, but
found no effect of ATG preparations in general [74,75] on the risk of
PTLD. The limited available retrospective data from liver [78] and lung
[76] patients also show no effect of rATG therapy on risk of PTLD. In
small bowel transplantation, one series has reported an increased rate
of PTLD in a series of children given rATG induction at a cumulative
dose of 7.5 mg/kg [77]. rATG in this study was given to the 16 patients
who had high titers of de novo donor-speciﬁc antibodies (DSA) (n =
11) or to treat rejection (n = 5). All other patients were given the IL-2
receptor antagonist basiliximab. During follow-up ranging from one to
nine years, six of the rATG-treated patients (37.5%) developed PTLD.
However, each of these patients also received sirolimus with
standard-exposure CNI, a combination which has been associated with
an unacceptably high rate of PTLD in children undergoing kidney trans-
plantation and, indeed, led to premature discontinuation of one study
due to PLTD risk [79]. It seems likely that these children undergoing
small bowel transplant were over-immunosuppressed, contributing to
the high rate of PTLD [77].
One retrospective study has described the occurrence of PTLD in a
series of 54 patients undergoing a second kidney transplant during
2004–2010who received a second course of rATG induction, comparing
this to a matched cohort of patients receiving rATG for the ﬁrst time,
after a primary kidney transplant [80]. The median total rATG dose
was 9 mg/kg in the retransplanted patients and 7 mg/kg in the primary
transplants. Only one case of PTLD was observed, in a control patient.
5. Pooled data
Marks and colleagues performed a systematic review to identify
published reports of PTLD in adult solid transplant recipients given
rATG induction [11]. Eleven studies were in kidney transplantation
(1392 patients in total) and ﬁve in heart transplantation (854 patients).
Seven were prospective studies, and four were retrospective analyses.
Themedian follow-up timewasﬁve years (range 3 to 10 years). The ob-
served rate of PTLD was 0.98% overall and 0.93% in kidney transplant
Table 4
Retrospective comparative analyses of PTLD risk according to induction therapy.
Study n Time of
transplant
Follow-up Induction group Comparator group/s PTLD
Kidney transplantation
Castro et al. [73] 763 1995–2001 ≥1 year rATG (n = 71) IL-2RA (n = 66), OKT3 (n = 44)
or no induction (n = 550)
rATG 0%, IL-2RA 0%, OKT3 0%, no
induction 0.4%
Hardinger et al. [68] 72 1996–1997 5 years rATG (n = 48) ATGAM (n = 24) rATG 0%, ATGAM 8.3% (n.s.)a
Bichari et al. [74] 1265 1979–2006 10 years ATG (type not speciﬁed) (n = 323) IL-2RA induction (n = 300), OTK3
(n = 21) or no induction (n = 621)
2.5% overall
Multivariate analysis showed no
difference in risk between ATG,
induction or no induction
(data not provided)
Kaden et al. [75] 760 1987–1998 5.5–17 years ATG-Fresenius
(single 9 mg/kg dose) (n = 522)
No induction (n = 238) 0.4% in both groups (p = 0.940)
Lung transplantation
Shyu et al. [76] 336 1998–2005 5 years rATG (n = 43) Alemtuzumb (n = 127), daclizumab
(n = 73) or no induction (n = 93)
rATG 3%, alemtuzumab 4%,
daclizumab 3%, no induction 6%
(p = 0.864)
Small bowel transplantation
Nassif et al. [77] 81 (children) 2003–2012 1–9 years rATG (n = 16) No ATG (IL-2RA in the majority
of cases) (n = 59)
rATG 37.5%, no rATG 5.1%b
ATGAM, equine thymocyte globulin; ATG-Fresenius, anti-human T-lymphocyte immunoglobulin from rabbits immunized with Jurkat cells; ATGAM, equine thymocyte globulin; IL-2RA,
interleukin 2 receptor alpha; n.s., not signiﬁcant; PTLD, post-transplant lymphoproliferative disorder; rATG, rabbit antithymocyte globulin; tx, transplantation.
a Signiﬁcantly lower rate of malignancy with rATG versus ATGAM (6% vs 21% p = 0.01).
b All six rATG-treated patients who developed PTLD received sirolimus in combination with standard-exposure tacrolimus; two of the patients additionally received rATG to treat
rejection.
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population overall [10]. The studies included in the analysis did not,
however, permit comparisons with no induction or other types of
induction agent since few were designed to compare rATG therapy
with other regimens.
Two Cochrane database analyses have included information on the
risk of PTLD after liver [71] or lung [81] transplantation. In both
analyses, no difference in the rate of PTLD was found between patients
given any type of T-cell antibody induction (including rATG, ATGAM
or ALG) versus no induction [71,81], but the robustness of the data
were limited by a relative paucity of studies.2.0
1.5
0.5
1.0
0
Incidence
of PTLD (%)
Overall
(n=2,246)
0.80
0.93 0.92 0.97
1.05
0.50
1.55
1.27
p=0.26
Kidney transplants
(n=1,392)
Heart transplants
(n=854)
Any rATG dose
rATG <7.5 mg/kg
rATG ≥7.5 mg/kg
p=0.92
p=0.18
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Fig. 1. Pooled analysis of incidence of PTLD in patients receiving rATG after kidney trans-
plantation (11 studies) or heart transplantation (5 studies) according to cumulative
rATG dose [11]. PTLD, post-transplant lymphoproliferative disease; rATG, rabbit
antithymocyte globulin.6. rATG and EBV infection
Given the well-established association between EBV infection and
risk of PTLD [6], it is interesting to note the ﬁndings of a retrospective
review undertaken in 197 pediatric liver transplant patients by Lu
et al. [78]. The incidence of EBV viremia at one year post-transplant
was not signiﬁcantly different in patients treated with rATG (73%) or
daclizumab (63%) and multivariate analysis found no effect of either
type of induction versus no induction on the risk of viremia. In one
cohort of 383 adult patients undergoing consecutive kidney transplants
during 2002 to 2010, the relatively high ATG-Fresenius dose of
21 mg/kg was associated with an increased risk of EBV infection
(p b 0.001) [82]. Since lowering immunosuppressive load is usually
effective in reducing the EBV viral load, this may have been an effect
of over-immunosuppression. Interestingly, in the US registry analysis
described by Kirk et al., a subpopulation analysis was undertaken in
EBV-seronegative children, who are known to be at high risk for PTLD
[17]. The relative risk of PTLD was found to be particularly high in the
EBV-seronegative children given rATG (8.56), a group that appears
vulnerable to over-immunosuppression.
An intriguing question is whether there is an interaction between
antiviral prophylaxis after transplantation and risk of PTLD under
rATG therapy. While prophylactic virostatic agents are primarily given
to prevent CMV infection, they can also suppress EBV infection [83,84]
and lower the rate of EBV-associated PTLD [19,20,85,86]. On ﬁrst sight,
these data are intriguing. Acyclovir, ganciclovir and valganciclovir arepro-drugs that require phosphorylation to become active. Phosphoryla-
tion occurs by the action of viral thymidine kinaseswhich are supposed-
ly inactive in EBV-infected B-cells during the latency program of the
virus. However, these thymidine kinases are active during the lytic
phase, and by reducing the dissemination of the virus, they may reduce
the pool of EBV-infected B-cells, the source of PTLD. This could explain
why acyclovir and ganciclovir have been found to exert a dramatic pre-
ventative effect on early PTLD in kidney recipients [85].
In the pooled analysis undertaken by Marks et al. described above
[11], the rate of PTLD in kidney or heart transplant patients given antivi-
ral prophylaxis was less than half that observed in patients without any
antiviral prophylaxis (0.63% versus 1.61%) [11]. Interestingly, in the
group who received antiviral prophylaxis (n = 1438), the rate of PTLD
was low regardless of whether rATG dose was b7.5 mg/kg (0.72%) or
≥7.5 mg/kg (0.30). The greatest inﬂuence on PTLD risk was absence of
antiviral prophylaxis, not use of induction therapy. These datamerit fur-
ther exploration.
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The pooled analysis of clinical trials byMarks et al. included an eval-
uation of the rate of PTLD according to the cumulative dose of rATG
(Fig. 1) [11]. Given that the conventional induction regimen for rATG
has been 1.5 mg/kg for ﬁve days, the authors used a cut-off point of
7.5 mg/kg. Overall, patients receiving less than this dose had a lower
observed rate of PTLD (0.80% versus 1.27% in those given 7.5 mg/kg or
more), but this differencewas largely conﬁned to heart transplant recip-
ients (Fig. 1) and all differences were non-signiﬁcant. Contemporary
regimens now typically apply a total rATG dose of 6 mg/kg [44,55],
below the cut-off used by Marks and colleagues.
One large single-center report, published only in abstract form to
date, has described 30 years' experience in 4809 kidney transplant pa-
tients, 1798 of whom received rATG [87]. Over the analysis period, the
initial dose of rATG remained unchanged at 7.5 mg/day, but the dura-
tion of administration steadily declined to less than 10 mg/kg. Mainte-
nance immunosuppression also evolved over the same period, but it
was noted that the incidence of PTLD fell from 4% to 1% over the most
recent 10 years.
Other data relating to rATG dose have generally been provided from
studies in children. One prospective assessment of 72 pediatric heart
transplant recipients found that patients who developed PTLD had re-
ceived a higher number of ATG doses than patients without PTLD
(mean4.3 versus 2.7, p=0.03) [21]. However, it is difﬁcult to drawcon-
clusions since induction therapy comprised only two doses. Subsequent
doses were given to treat rejection i.e. those patients receiving higher
doses had experienced rejection. Moreover, several different ATG
preparations were given i.e. rATG, ATGAM, and ATG-Fresenius (ATG-
Fresenius is an anti-human T-lymphocyte immunoglobulin from rabbits
immunized with Jurkat cells). An early analysis from the same center
prospectively assessed EBV load and risk of PTLD in 41 children under-
going heart transplantation, but only 20% received rATG (67% received
horse ATGAM) [88]. With this caveat, it is still of interest to note that
the mean number of doses of ATG (of any type) was higher in patients
who developed PTLD versus no PTLD (mean 4.2 versus 1.8 doses; p =
0.03). There are, however, reports of low rates of lymphoma in pediatric
recipients of a heart transplant despite high doses of rATG: for example,
Di Filipppo et al. found only one case of PTLD during 10 years' follow-up
in 33 patients given up to 8 mg/kg of rATG [89].
8. Conclusions
Accurate assessment of the risk of PTLD in solid organ transplant pa-
tients under rATG induction is challenging. The beneﬁts of high patient
numbers and long duration of follow-up provided by registry analyses
are offset by older datasets, by inclusion of multiple induction agents
with no differentiation between polyclonal preparations, doses or
duration of therapy, and by the risk of incomplete adjustment for selec-
tion bias. A major bias is the burden of immunosuppression during the
maintenance phase of the graft. In renal transplantation, most centers
preferentially use rATG, as opposed to non-depleting agents, for pa-
tients at high immunological risk. These patients typically also receive
higher doses of CNI and steroids over the long term, and have a higher
incidence of acute rejection episodes which, in turn, require additional
anti-rejection therapies. Because PTLD is a viral disease, facilitated by a
decrease in cellular immunity, any study which aims to isolate the role
of a speciﬁc agent in the development of PTLD should adjust for the cu-
mulative effect of all other immunosuppressive drugs administrated in
the recipient before the onset of PTLD,which is never the case in registry
analyses.
Randomized trials cannot provide meaningful data on the risk of
PTLD associated with rATG administration due to their small size and
short duration. Retrospective studies, often involving relatively high
numbers of patients, do not indicate any increased risk for PTLD with
rATG but are inherently less reliable than prospective controlled trials.In general, concerns about an increased risk of PTLD with rATG induc-
tion after solid organ transplantation stem largely from registry studies
with poor methodology and which do not take account of dosing or
length of treatment. These have analyzed patient cohorts transplanted
when rATG doses were higher than today andwhenmanagement prac-
tices were different, such as lower use of antiviral prophylaxis.
While the available data give no clear guidance, it would seem rea-
sonable to employ the lowest dose of rATG compatiblewith effective in-
duction. Recent reviews concluded that a cumulative dose of 6 mg/kg is
generally appropriate for use as induction therapy after solid organ
transplantation [44,56]. Although data are limited to one pooled analy-
sis, it is possible that patients receiving antiviral prophylaxis are less
vulnerable to an effect of high rATG doses. Careful use of rATG may be
warranted in EBV-seronegative recipients who do not receive antiviral
therapy, particularly in children and other high-risk groups such as
heart–lung transplant recipients. In children, it has been suggested
that a maximum cumulative rATG dose of 3–4.5 mg/kg may be appro-
priate [56].
In conclusion, modern immunosuppressive regimens employ
rATG induction at doses which are markedly lower than in the past,
and minimize maintenance dosing regimens with modiﬁcation of both
induction and maintenance therapy in at-risk patients. In such circum-
stances, the risk of PTLD does not appear to be an important contributor
to the risk beneﬁt balance associated with rATG induction.
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